The effect of cytomegalovirus (CMV) infection on 1-year mortality rates among allogeneic bone marrow transplant recipients who are receiving a standard protocol as prophylaxis for CMV infection is unclear. We determined the risk factors for death within 1 year among 103 bone marrow transplant recipients by performing a multivariate analysis. The results of donor and recipient CMV serologies did not predict 1-year mortality, although there was a trend towards higher mortality among CMVseropositive recipients who received marrow from seronegative donors (P Å .077). Multivariate analysis revealed that the factors independently associated with 1-year mortality were the develop- Allogeneic bone marrow transplantation (BMT) is increasnificant reduction in the incidence of active CMV disease with prophylactic ganciclovir therapy for patients with CMV-posiingly being performed for the treatment of hematologic distive cultures of bronchoalveolar lavage (BAL) fluid obtained eases. The development of numerous infectious and noninfecon day 35 after BMT. However, no improvement in survival tious complications after BMT results in significant mortality was demonstrated, possibly because of the adverse effects of despite therapeutic and prophylactic measures. Determination ganciclovir. Ganciclovir is currently used as prophylaxis for of risk factors that are predictive of increased mortality would CMV infection at our institution. However, the overall effect help in identifying patients who are candidates for closer moniof this intervention on 1-year mortality has not been examined toring and more aggressive prophylactic or therapeutic interin a multivariate analysis. ventions.
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Studies examining risk factors for death after BMT have Disease caused by cytomegalovirus (CMV) has been shown focused on demographic data for recipients (specifically age), to be a significant cause of morbidity and mortality among the presence of acute GVHD, conditioning and GVHD prophybone marrow transplant recipients [1, 2] . The risk of CMV laxis regimens, and specific underlying disease variables disease has been related to seropositivity for CMV before BMT, [8 -12] . The effects of pretransplantation CMV serostatus and the presence of graft-versus-host disease (GVHD), and older the development of CMV infection and CMV disease after age [3, 4] . Pretransplantation CMV serostatus has been corretransplantation on 1-year mortality have not been fully elucilated with 1-year mortality among liver transplant recipients dated in a multivariate analysis. Although one study demon- [5] . Numerous strategies have been used in studies evaluating strated a correlation between the development of CMV antigenprophylactic therapy with ganciclovir in bone marrow transemia and death, the results of this study were confounded by plant recipients [6, 7] . Schmidt et al. [6] demonstrated a sigthe fact that patients received CMV prophylaxis on the basis of antigenemia assay results [13] . Therefore, we performed a multivariate analysis to evaluate the correlation between pretransplantation CMV serostatus, posttransplantation CMV in-and 5 May 1996 were eligible for inclusion in this study. After tioning protocols included cyclophosphamide with or without busulfan or cyclophosphamide with or without ara-C plus total informed consent was obtained, specimens for antigenemia assays and blood, urine, and throat cultures for CMV were body irradiation, depending on the underlying diagnosis and disease status. Patients were classified as having advanced or collected weekly from day 0 to day 100 after BMT. This has been shown to be the peak period for reactivation of CMV early disease on the basis of pretransplantation status. Patients with relapsed acute leukemia after the first complete remission, infection after BMT [1] . As part of our standard BMT protocol, all CMV-seropositive recipients and all recipients whose dochronic leukemia in the accelerated phase, multiple myeloma, non-Hodgkin's lymphoma, or myelodysplastic syndrome were nors were CMV seropositive underwent screening bronchoscopy on day 35 to obtain BAL fluid for culture. All patients classified as high-risk (advanced disease), and all other patients were classified as low-risk (early disease). with BAL fluid positive for CMV were treated prophylactically with intravenous ganciclovir (10 mg/[kgrd] for 2 weeks) and received maintenance therapy (6 mg/[kgrd] for 8 weeks).
Patients
These patients received blood and blood products that had not been screened for CMV.
A total of 103 bone marrow transplant recipients were evaluated over the study period. Underlying diagnoses included Seronegative recipients of seronegative donor marrow did not undergo screening bronchoscopy on day 35 and received chronic myelogenous leukemia (n Å 35), acute myelogenous leukemia (n Å 22), myelodysplastic syndrome (n Å 11), acute only CMV-negative blood and blood products. Patients did not receive immunoglobulin for the prevention of CMV disease. lymphocytic leukemia (n Å 13), non-Hodkgin's lymphoma (n Å 9), multiple myeloma (n Å 5), chronic lymphocytic leukeThe results of cultures of blood, urine, and throat specimens and the antigenemia assays were not disclosed, and none of mia (n Å 4), aplastic anemia (n Å 3), and myelofibrosis (n Å 1). The overall mortality at 1 year was 30% (31 of 103 the patients received prophylaxis for CMV infection on the basis of the results of these assays. Symptomatic patients with patients). The mean age of recipients was 40.1 years (range, 17 -61 years) and did not differ between survivors and nonsur-CMV infection or disease (see below for definitions) were treated with ganciclovir or foscarnet, with or without immunovivors (39.4 years vs. 42.0 years; P Å not significant). Seventy recipients were male, and 33 were female. Since the purpose globulin, at the discretion of the primary physician.
Demographic data, results of donor and recipient CMV serolof this study was to examine the effect of CMV infection and disease on outcome, four patients were excluded from ogies, disease status at BMT, data on GVHD, and 1-year survival outcomes were gathered prospectively. All tests were the analysis of posttransplantation variables because samples collected for evaluation for CMV infection were inadequate. performed prospectively on freshly obtained samples. Data on development of active CMV disease were obtained by retroThree of these patients died of causes unrelated to CMV infection in the immediate weeks following transplantation and the spectively reviewing patients' charts. Pretransplantation donor and recipient CMV serologies were determined by using the fourth patient was followed up at another institution after discharge from the BMT unit. Abbott AxSYM enzyme immunoassay (Abbott Laboratories, Abbott Park, IL). Posttransplantation antigenemia assays and shell vial and tube cultures of throat, urine, blood, and BAL
Statistical Methods
specimens were processed according to standard methods, as previously described [14] .
Variables were analyzed for their association with death 1 year after transplantation. A logrank test from the Kaplan-CMV infection was defined as recovery of CMV in any shell vial or tube culture or as a positive antigenemia assay. CMV Meier survival analysis was used for categorical pretransplantation variables. For continuous pretransplantation variables and disease was defined as evidence of CMV infection with associated signs and symptoms. Criteria for the diagnosis of CMV posttransplantation variables, a Wald x 2 test from the Cox proportional hazards survival analysis was used. For the multidisease were used as previously described [15] . CMV pneumonia was defined as the presence of compatible clinical sympvariate analysis, variables that were significantly associated with 1-year mortality (P õ .05) on univariate analysis were toms and chest radiographic findings, together with the detection of CMV in BAL fluid or a lung biopsy specimen.
included and analyzed by using a stepwise Cox proportional hazards regression model. Gastrointestinal disease was defined as the presence of symptoms and the detection of CMV in biopsy specimens. CMV viral syndrome was defined as unexplained fever in association Results with leukopenia or thrombocytopenia [16] . Acute GVHD was defined according to current clinical criteria [2] .
Active CMV disease was present at the time of death in only three of 31 patients. CMV disease was not considered the GVHD prophylaxis consisted of cyclosporin A and methotrexate [2] . Recipients of transplants from unrelated donors sole cause of death in any of the cases. Death was attributed to disease relapse (n Å 3), bacterial sepsis (n Å 5), fungal received cyclosporin A, methotrexate, and corticosteroids. T cell depletion of donor bone marrow was not performed. Condiinfection (n Å 4), multiple factors (n Å 12), acute GVHD / 9c48$$mr08 02-05-98 21:52:17 cida UC: CID (n Å 4), severe veno-occlusive disease (n Å 2), and hemorrhage an increased 1-year mortality. CMV antigenemia assays were positive a median of 48.5 days after BMT (mean, 46.0 days) (n Å 1). The median time to death was 130 days after BMT. Three patients had CMV pneumonitis at the time of death, as for the patients who survived, vs. 40.0 days (mean, 40.8 days) for the patients who died (P Å not significant). Blood cultures well as fungal infection (n Å 2), Pneumocystis carinii pneumonia (n Å 1), or bacterial sepsis (n Å 1). Of 13 additional patients for CMV were positive a median of 42.0 days (mean, 44.3 days) after BMT, and there was no significant difference bewith CMV disease, eight had CMV pneumonitis, two had gastrointestinal disease, and three had CMV viral syndrome.
tween patients who were alive or dead at 1 year. Three patients had positive BAL fluid specimens, CMV antigenemia, and The results of univariate analysis are shown in table 1. Analysis of pretransplantation variables showed that the probability positive CMV blood cultures, and all of these patients died within the first year after BMT. of dying within the first year after BMT was higher for patients with advanced disease (as defined in Methods) pretransplantion
Variables that were significant (P õ .05) in the univariate analysis were included as factors for multivariate analysis (table and for recipients of allografts from unrelated donors. The pretransplantation CMV serostatus of donors and recipients 2). The development of CMV antigenemia after BMT, the was not a statistically significant predictor of 1-year mortality, although there was a trend towards increased mortality for Urine, blood, or throat cultures positive for CMV were not associated with a higher probability of death. For the subset NOTE. CMV Å cytomegalovirus; GVHD Å graft-versus-host-disease.
of 67 patients who underwent screening bronchoscopy for * Multivariate analysis performed using a stepwise Cox proportional hazards regression model. CMV on day 35, a positive BAL result was associated with / 9c48$$mr08 02-05-98 21:52:17 cida UC: CID development of severe acute GVHD, and the use of unrelated The presence of CMV antigenemia was a better marker of the reactivation of CMV infection than were blood, urine, or throat donors remained independent predictors of 1-year mortality. Multivariate analysis showed that the development of active cultures positive for CMV. None of these latter investigations were predictive of 1-year mortality. CMV disease and advanced pretransplantation hematologic disease did not contribute significantly to mortality. In a separate
In the subgroup of 67 patients who underwent screening bronchoscopy on day 35, those with BAL specimens positive multivariate analysis of the 67 patients who underwent screening bronchoscopy on day 35, a positive BAL result was not for CMV had a threefold relative risk of death at 1 year (on univariate analysis) despite the use of prophylactic ganciclovir independently associated with increased mortality (P Å .68; RR Å 1.26; CI Å 0.47 -3.77). CMV antigenemia, unrelated therapy. Of the 10 patients with positive BAL fluid specimens, two developed active CMV disease, and six died. In a previous donors, and severe acute GVHD remained independent predictors of mortality for this subgroup. study analyzing the clinical utility of screening bronchoscopy on day 35, patients received immunoglobulin both before and during prophylactic treatment with ganciclovir [6] . Since imDiscussion munoglobulin was not given to this group of patients, except for the treatment of active CMV pneumonitis, it is unknown Pretransplantation recipient and donor CMV serologies were not correlated with 1-year mortality for our cohort of allogeneic whether the nonuse of immunoglobulin may have had an effect on outcome. BMT recipients who received ganciclovir prophylaxis based on the results of screening bronchoscopy for CMV on day Our findings are in agreement with the results published by Bacigalupo et al. [13] , who also demonstrated a correlation be-35. Despite this finding, there was a trend towards increased mortality among seropositive recipients with seronegative dotween the development of CMV antigenemia and BMT-related mortality. They were also able to show increased mortality among nors. Previous studies have demonstrated that the risk of developing CMV disease is increased for seropositive recipients, patients with higher levels of antigenemia. However, in that study, patients with antigenemia were prophylactically treated regardless of donor status, although this finding was not correlated with 1-year mortality [3] . Similarly, Grob et al. [17] with ganciclovir or foscarnet. Therefore, the true mortality associated with reactivation of CMV infection may have been condemonstrated that the risk of CMV pneumonitis and fatal CMV disease was significantly higher for CMV-seropositive recipifounded by treatment efficacy and/or drug-related adverse effects. We were blinded to the results of the antigenemia assays and ents of marrow from seronegative donors than for recipients of marrow from seropositive donors. This situation contrasts cultures of blood, urine, and throat specimens, and none of the patients received prophylactic therapy based on the result of with that in solid organ transplantation, where higher rates of CMV disease and higher 1-year mortality have been reported these assays. Thus, our results provide a better evaluation of the correlation between these assays and 1-year mortality. for seronegative recipients of organs from seropositive donors [5] . Seropositive marrow donors may transfer partial cellular Although a trend towards higher mortality among patients with higher CMV antigen levels was observed in our study, immunity to the recipients, thereby conferring protection against CMV infection, which would account for the difference this trend was not statistically significant (data not shown).
Other investigators have shown that the mortality rate among between bone marrow transplant recipients and solid organ transplant recipients.
recipients of marrow from unrelated donors is higher than that among recipients of marrow from related donors [21] . The The increase in 1-year mortality for patients who developed CMV infection, as documented by positive CMV antigenemia correlation between acute GVHD and transplantation-related mortality has also been previously documented [10, 12] . The assays, was greater than 2.5-fold. This variable remained significant on multivariate analysis and was independent of the results of the multivariate analysis in our study are in agreement with these findings. development of active CMV disease. It is of interest that the development of active CMV disease was not associated with
The limitations of our study include the relatively small sample size. For this reason, patients could not be analyzed according to increased mortality, possibly because of advances in early recognition and treatment that may have resulted in somewhat pretransplantation diagnosis or conditioning regimen and were therefore grouped into early or advanced disease categories on the better outcomes than have been reported in previous studies [18] . Reactivation of CMV infection may represent a marker of basis of disease status at the time of BMT. In addition, conclusions derived from this cohort of patients must be interpreted on the overall poor immune reconstitution after BMT, or alternatively, may contribute to further immunosuppression, thereby rebasis of this small sample size. Although most of the patient data and all the laboratory investigations were gathered and performed sulting in increased mortality associated with other causes. This is supported by previously published in vitro data that prospectively, data about the development of active CMV disease was gathered by retrospective chart review. This methodology demonstrated delayed immunologic recovery in bone marrow transplant recipients with CMV infection or disease [19] . Furmay have resulted in potential biases, although whenever possible, retrospective data were gathered without knowledge of the results thermore, CMV infection has been recognized as a risk factor for the development of bacterial and fungal infections [20] .
of CMV laboratory investigations.
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